Nab paclitaxel / gemcitabine

DRUG4 trials

Sponsors

Helse Stavanger HF, iOnctura, ImmunityBio, Inc., Federation Francophone de Cancerologie Digestive

Conditions

Borderline Resectable Pancreatic Ductal AdenocarcinomaHealthyMetastatic Pancreatic CancerPancreatic CancerPancreatic Cancer Resectable

Phase 1

A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers

CompletedNCT05027568

iOncturaHealthy

Start: 2021-06-28End: 2021-09-07Updated: 2025-03-20

Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

Not yet recruitingNCT07488884

ImmunityBio, Inc.Pancreatic Cancer, Pancreatic Cancer Resectable

Start: 2026-06-01End: 2029-06-01Target: 30Updated: 2026-04-29

Phase 2

Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients

CompletedNCT02707159

Helse Stavanger HFMetastatic Pancreatic Cancer

Start: 2014-11-30End: 2019-01-31Updated: 2023-03-08

Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.

Not yet recruitingNCT07616362

Federation Francophone de Cancerologie DigestiveBorderline Resectable Pancreatic Ductal Adenocarcinoma

Start: 2026-06-01End: 2031-04-01Target: 110Updated: 2026-06-11